UT MD Anderson Cancer Center Network Lead Academic Participating Site (LAPS) UG1

$1,404,649UG1FY2025CANIH

University Of Tx Md Anderson Can Ctr, Houston TX

Investigators

Anne S Tsaocontact Chelsea Camille Pinnix

Linked publications & trials

Paper 39446327 Paper 39371185 Paper 39296880 Paper 39282913 Paper 39169033 Paper 39008208 Paper 38942046 Paper 38640040 Paper 38492812 Paper 38236702 Paper 38236590 Paper 37938495 Paper 37651652 Paper 37615099 Paper 37531248 Paper 37524096 Paper 37334719 Paper 37322121 Paper 37272534 Paper 37053535 Paper 37050880 Paper 36977292 Paper 36856617 Paper 36662819 Paper 36653664 Paper 36623230 Paper 36602784 Paper 36521078 Paper 36493334 Paper 36472389 Paper 36260828 Paper 36067452 Paper 35945621 Paper 35834226 Paper 35653124 Paper 35233056 Paper 35133871 Paper 34914339 Paper 34890060 Paper 34699271 Paper 34636255 Paper 34608052 Paper 34554848 Paper 34374082 Paper 34092112 Paper 33894496 Paper 33765513 Paper 33358401 Paper 33258687 Paper 33136585 Paper 33125909 Paper 33095682 Paper 33048619 Paper 32866432 Paper 32808160 Paper 32699926 Paper 32678879 Paper 32586939 Paper 32125937 Paper 31969335 Paper 31924734 Paper 31702432 Paper 31665365 Paper 31623857 Paper 31504139 Paper 31418130 Paper 31358544 Paper 31314062 Paper 31216226 Paper 31195180 Paper 31138522 Paper 31085287 Paper 30917258 Paper 30575484 Paper 30204536 Paper 30193295 Paper 30130544 Paper 30080730 Paper 30037817 Paper 29987605 Paper 29801011 Paper 29789969 Paper 29709410 Paper 29588392 Paper 28947566 Paper 28898379 Paper 28826616 Paper 28766207 Paper 28756902 Paper 28687377 Paper 28657941 Paper 28599887 Paper 28453704 Paper 28438473 Paper 28244413 Paper 28185892 Paper 28174234 Paper 28143870 Paper 28073578 Paper 28055108

Abstract

PROJECT SUMMARY Clinical trials are an integral part of MD Anderson Cancer Centerâs (MDACC) mission. In FY2023, we cared for approximately 179,000 patients and enrolled more than 9,600 patients on nearly 1,500 interventional studies. MDACC has made significant contributions to the former NCI cooperative groups and the new National Clinical Trial Network (NCTN), including robust trial enrollment, scientific and administrative leadership, and mentoring early career faculty to participate in these important national trials. For FY 2019-2024, at MDACC, 1429 patients were enrolled in NCTN Network group clinical trials, including 1081 patients in therapeutic treatment trials resulting in an average of > 200 patients per year. Centralized coordination of NCTN activities at our institution has facilitated the development and conduct of multidisciplinary, innovative trials. This participation has led to opportunities for service through various NCTN leadership roles. Our institution has also sponsored talented clinical and translational investigators to apply for NCTN membership, provided mentorship of early career faculty, and encouraged applications for NCTN peer-reviewed grant funding. These activities have contributed to the success of the NCTN LAPS UG1 grant as well as working towards the fulfillment of our mission of eliminating cancer in Texas, nationally, and globally through advances in cancer treatment, research and education. Our goals will continue with the supplement request of the NCTN LAPS UG1 grant.

View original record on NIH RePORTER →